Disparities in COVID-19 incidence and fatality rates at high-altitude

PeerJ. 2023 Feb 6:11:e14473. doi: 10.7717/peerj.14473. eCollection 2023.

Abstract

Background: SARS-CoV-2 has affected every demography disproportionately, including even the native highland populations. Hypobaric-hypoxic settings at high-altitude (HA, >2,500 masl) present an extreme environment that impacts the survival of permanent residents, possibly including SARS-CoV-2. Conflicting hypotheses have been presented for COVID-19 incidence and fatality at HA.

Objectives: To evaluate protection or risk against COVID-19 incidence and fatality in humans under hypobaric-hypoxic environment of high-altitude (>2,501 masl).

Methods: Global COVID-19 data of March 2020-21, employed from official websites of the Indian Government, John Hopkins University, and Worldometer were clustered into 6 altitude categories. Clinical cofactors and comorbidities data were evaluated with COVID-19 incidence and fatality. Extensive comparisons and correlations using several statistical tools estimated the risk and protection.

Results: Of relevance, data analyses revealed four distinct responses, namely, partial risk, total risk, partial protection, and total protection from COVID-19 at high-altitude indicating a mixed baggage and complexity of the infection. Surprisingly, it included the countries within the same geographic region. Moreover, body mass index, hypertension, and diabetes correlated significantly with COVID-19 incidence and fatality rate (P ≤ 0.05).

Conclusions: Varied patterns of protection and risk against COVID-19 incidence and fatality were observed among the high-altitude populations. It is though premature to generalize COVID-19 effects on any particular demography without further extensive studies.

Keywords: COVID-19; Cofactors; Comorbidities; High-altitude; Protection; Risk.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Altitude
  • COVID-19* / epidemiology
  • Diabetes Mellitus*
  • Humans
  • Hypoxia / epidemiology
  • Incidence
  • SARS-CoV-2

Grants and funding

We received the support of the Cardiovascular Medical Research and Education, Philadelphia, USA (IGIB grant code CLP0032; BAA, NC); CSIR-UGC, New Delhi (ref (21/06/2015(i)EU-V; T.P.); and Indian Council of Medical Research, New Delhi, India (ICMR No. 74/6/2015- Pers. EMS; QP). No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.